Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accretion PharmaceuticalsNSE:ACCPL +2.26%18 PB Ratio is 3.27 as of Jul. 16, 2026, which is 40% above its 10-year median of 2.34. GuruFocus rates NSE:ACCPL with a GF Score™ of 18/100. The stock has 6 warning signs investors should review. Among 922 Drug Manufacturers companies, Accretion Pharmaceuticals ranks worse than 70.07% on this metric.
Accretion Pharmaceuticals Ltd stock PB Ratio (=3.19) is close to 1-year high of 3.19.
The historical rank and industry rank for Accretion Pharmaceuticals's PB Ratio or its related term are showing as below:
NSE:ACCPL'
s PB Ratio Range Over the Past 10 Years
Min: 1.37 Med: 2.34 Max: 3.26
Current: 3.26
During the past 5 years, Accretion Pharmaceuticals's highest PB Ratio was 3.26. The lowest was 1.37. And the median was 2.34.
NSE:ACCPL's PB Ratio is ranked worse than 70.07% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.955
vs NSE:ACCPL: 3.26
During the past 3 years, the average Book Value Per Share Growth Rate was 145.40% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Accretion Pharmaceuticals was 145.40% per year. The lowest was 145.40% per year. And the median was 145.40% per year.
Back to Basics: PB Ratio
Accretion Pharmaceuticals (NSE:ACCPL) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Accretion Pharmaceuticals PB Ratio Related Terms
Accretion Pharmaceuticals PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Accretion Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accretion Pharmaceuticals PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accretion Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Accretion Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Accretion Pharmaceuticals (NSE:ACCPL) has a PB Ratio of 3.27 as of Jul. 16, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Accretion Pharmaceuticals and its competitors. This is 40% above median its historical median of 2.34. Over the past decade, Accretion Pharmaceuticals' PB Ratio has ranged from 1.37 to 3.26. According to the industry distribution chart, Accretion Pharmaceuticals ranks #646 out of 922 companies in the Drug Manufacturers industry, placing it in the top 70.1%.
Is Accretion Pharmaceuticals' PB Ratio too high?
Accretion Pharmaceuticals' current PB Ratio of 3.27 is 40% above median its 10-year median of 2.34. Over the past 10 years, this metric has ranged from a low of 1.37 to a high of 3.26. The Drug Manufacturers industry median PB Ratio is 1.96. Accretion Pharmaceuticals' value of 3.27 is 67.3% above this industry median. Based on the distribution chart, Accretion Pharmaceuticals ranks #646 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Accretion Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Pharmaceuticals' PB Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Accretion Pharmaceuticals ranks #646 out of 922 companies for PB Ratio. This places Accretion Pharmaceuticals in the lower half of its industry. The industry median PB Ratio is 1.96. Accretion Pharmaceuticals' value of 3.27 is 67.3% above this benchmark. Historically, Accretion Pharmaceuticals' own PB Ratio has ranged from 1.37 to 3.26 over the past decade. While the company's 10-year median is 2.34 vs. the industry median of 1.96, Accretion Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.96, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accretion Pharmaceuticals's current PB Ratio of 3.27 is 67.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Accretion Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Pharmaceuticals's current PB Ratio is 3.27, which is 40% above median its own 10-year median of 2.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Pharmaceuticals stock overvalued right now?
Accretion Pharmaceuticals (NSE:ACCPL) has a current PB Ratio of 3.27. The current PB Ratio is 3.27, which is 40% above median its 10-year median of 2.34 and 67.3% above the Drug Manufacturers industry median of 1.96. Accretion Pharmaceuticals' overall GF Score™ is 18/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Accretion Pharmaceuticals (NSE:ACCPL), the current PB Ratio is 3.27 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accretion Pharmaceuticals Ltd is engaged in the manufacturing of Medicinal & Pharmaceutical Products. The company manufactures tablets, oral liquid, capsule, cream, ointment, mouthwash, dusting powder, gel, ear drops, lotion, shampoo, powder, syrup, among others.
18GF Score
Get the complete analysis for NSE:ACCPL
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ACCPL has been successfully added to your 
